Bolor Ulziitsogt
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Bolor Ulziitsogt has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Batbold Batsaikhan
Department of Internal Medicine, Institute of Medical Sciences, Ministry of Economy and Development, Ulaanbaatar 14210, Mongolia
1 shared publication - Chuluunbileg Batbold
Department of Internal Medicine, Institute of Medical Sciences, Ministry of Economy and Development, Ulaanbaatar, Mongolia
1 shared publication - Ganchimeg Dondov
Department of Internal Medicine, Institute of Medical Sciences, Ministry of Economy and Development, Ulaanbaatar 14210, Mongolia
1 shared publication - Gantogtokh Dashjamts
Department of Internal Medicine, Institute of Medical Sciences, Ministry of Economy and Development, Ulaanbaatar 14210, Mongolia
1 shared publication - Tegshjargal Badamjav
Department of Internal Medicine, Institute of Medical Sciences, Ministry of Economy and Development, Ulaanbaatar 14210, Mongolia
1 shared publication - Tsogdulam Sumiyabazar
Department of Internal Medicine, Institute of Medical Sciences, Ministry of Economy and Development, Ulaanbaatar, Mongolia
1 shared publication
Latest Publications
- Open Access
- 25 March 2026
- Published by American Society for Inclusion, Diversity, and Equity in Healthcare in ASIDE Oncology
- Vol. 1 (2) , 1-10
The Relationship Between pks+ Escherichia coli and Colorectal Cancer: A Review
Introduction: According to GLOBOCAN estimates, colorectal cancer (CRC) was the third most common cancer worldwide in 2020, comprising 11% of all cancer diagnoses. Researchers’ interest in CRC development has shifted toward the gastrointestinal microbiome, especially the mutagenicity of pks+ E. coli. Therefore, we aimed to review the current evidence on the relationship between pks+ E. coli and CRC. Method: We reviewed the literature reporting the association between pks+ E. coli and CRC, which was obtained from three databases: PubMed, Google Scholar, and the Cochrane Library, published between January 2021 and January 2026. We used the following keywords for our search strategy: pks, Escherichia coli, and colorectal cancer. Result: As stated in the original studies, the contribution of pks+ E. coli to CRC development was associated with a higher prevalence in the CRC group than in the healthy group. However, these results are inconsistent across the studies. Conclusion: Given the limited evidence, researchers should conduct larger cohort studies to clarify this relationship and identify other factors contributing to the presence of pks+ E. coli, particularly across diverse clinical settings. Furthermore, clinical translation, such as the utilization of screening or therapeutic biomarkers, requires prospective validation and standardized detection methods.
- 25 March 2026
- Published by American Society for Inclusion, Diversity, and Equity in Healthcare in ASIDE Oncology
- Vol. 1 (2) , 1-10
Open AccessThe Relationship Between pks+ Escherichia coli and Colorectal Cancer: A Review
Introduction: According to GLOBOCAN estimates, colorectal cancer (CRC) was the third most common cancer worldwide in 2020, comprising 11% of all cancer diagnoses. Researchers’ interest in CRC development has shifted toward the gastrointestinal microbiome, especially the mutagenicity of pks+ E. coli. Therefore, we aimed to review the current evidence on the relationship between pks+ E. coli and CRC. Method: We reviewed the literature reporting the association between pks+ E. coli and CRC, which was obtained from three databases: PubMed, Google Scholar, and the Cochrane Library, published between January 2021 and January 2026. We used the following keywords for our search strategy: pks, Escherichia coli, and colorectal cancer. Result: As stated in the original studies, the contribution of pks+ E. coli to CRC development was associated with a higher prevalence in the CRC group than in the healthy group. However, these results are inconsistent across the studies. Conclusion: Given the limited evidence, researchers should conduct larger cohort studies to clarify this relationship and identify other factors contributing to the presence of pks+ E. coli, particularly across diverse clinical settings. Furthermore, clinical translation, such as the utilization of screening or therapeutic biomarkers, requires prospective validation and standardized detection methods.